# Gustave Roussy, Cancer Campus, Grand Paris: Phase 3 study in Osteosarcoma, Pediatric Osteosarcoma (530 participants)

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Sponsor type | Academic and hospital |
| Study | Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse |
| NCT ID | NCT07871864 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Osteosarcoma; Pediatric Osteosarcoma; Osteosarcoma in Children; Osteosarcoma in Adolescents and Young Adults; Osteosarcoma Metastatic |
| Intervention types | drug |
| Target enrollment | 530 |
| Site countries | Denmark, Finland, France, Italy, Netherlands, Poland, Spain, Sweden |
| Posted | 2026-10-13 |
| Planned start | 2026-10-07 |
| Event | Newly registered study |
| Event date | 2026-10-13 |

## Why this score
- Phase 3: multi-site, larger budget.
- 530 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07871864). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.